Reports Q1 revenue $5.283M vs $1.230M last year. “Lifeward has experienced a transformation of the market with the finalized Medicare payment for ReWalk personal exoskeletons for eligible beneficiaries,” said Larry Jasinski, Chief Executive Officer of Lifeward. “Our Medicare claims have begun to be processed and approved for payment and this signifies a significant expansion of access to the ReWalk technology for individuals with spinal cord injury (“SCI”).”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFWD:
- Lifeward to Report First Quarter Financial Results on May 15, 2024
- ReWalk Robotics Welcomes Michael Swinford to Board
- Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
- Lifeward appoints Swinford to board of directors
- Lifeward price target raised to $9 from $3 at H.C. Wainwright